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1. INTRODUCTION {#ags312291-sec-0005}
===============

Despite remarkable progress in the field of colorectal surgery, postoperative complications remain a major problem during the course of colorectal cancer treatment.[1](#ags312291-bib-0001){ref-type="ref"}, [2](#ags312291-bib-0002){ref-type="ref"}, [3](#ags312291-bib-0003){ref-type="ref"}, [4](#ags312291-bib-0004){ref-type="ref"} After colorectal surgery, postoperative ileus (POI) occurs at a frequency of 10%‐17%, resulting in longer hospital stays and higher costs.[3](#ags312291-bib-0003){ref-type="ref"}, [4](#ags312291-bib-0004){ref-type="ref"}, [5](#ags312291-bib-0005){ref-type="ref"}, [6](#ags312291-bib-0006){ref-type="ref"}, [7](#ags312291-bib-0007){ref-type="ref"} POI is characterized by lack of bowel sounds, delayed passage of flatus and stool, abdominal distension, nausea, vomiting, and pain.[5](#ags312291-bib-0005){ref-type="ref"}, [7](#ags312291-bib-0007){ref-type="ref"} Postoperative complications, including POI, after surgery for rectal cancer are reportedly associated with delays in adjuvant chemotherapy, and patients who receive delayed adjuvant chemotherapy have worse recurrence rates and worse overall survival than patients who receive chemotherapy within 8 weeks of surgery.[8](#ags312291-bib-0008){ref-type="ref"} Preoperative identification of risk factors could enable improved postoperative management for patients at higher risk of complications.

Prior studies have assessed the risk factors for POI, including male gender, peripheral vascular disease, respiratory comorbidity, preoperative albumin, stoma construction, operation lasting over 3 hours, conversion to open surgery, and intra‐abdominal surgical site infection.[3](#ags312291-bib-0003){ref-type="ref"}, [5](#ags312291-bib-0005){ref-type="ref"}, [9](#ags312291-bib-0009){ref-type="ref"} Compared to open surgery, laparoscopic colorectal surgery is associated with lower incidence of postoperative bowel obstruction.[10](#ags312291-bib-0010){ref-type="ref"} Some studies have reported that body mass index (BMI), which is widely used for the assessment of general obesity, is also a risk factor for POI.[6](#ags312291-bib-0006){ref-type="ref"}, [11](#ags312291-bib-0011){ref-type="ref"} However, recent findings suggest that, compared to BMI, visceral obesity (VO) is more strongly associated with complications after colorectal surgery.[12](#ags312291-bib-0012){ref-type="ref"}, [13](#ags312291-bib-0013){ref-type="ref"} In an analysis of 338 consecutive patients with colon cancer, Watanabe et al reported that VO was more strongly related to the incidence of anastomotic leakage and surgical site infection than high BMI.[13](#ags312291-bib-0013){ref-type="ref"} However, to the best of our knowledge, no study has shown that VO is a risk factor for POI after surgery for colorectal cancer.

In the present study, we assessed whether VO is a risk factor for POI among patients with primary colorectal cancer.

2. METHODS {#ags312291-sec-0006}
==========

2.1. Study population {#ags312291-sec-0007}
---------------------

This study involved patients with primary colorectal cancer who underwent elective surgery at Osaka University Hospital between January 2010 and December 2012. We included patients who underwent one of 12 surgical procedures: ileocecal resection, right hemicolectomy, transverse colectomy, left hemicolectomy, sigmoidectomy, anterior resection, low anterior resection, super‐low anterior resection, abdominoperineal resection, intersphincteric resection, Hartmann\'s operation, or total pelvic exenteration. Patients who underwent subtotal colectomy, total colectomy, or two different procedures (eg, ileocecal resection and sigmoidectomy) were systematically excluded (Figure [1](#ags312291-fig-0001){ref-type="fig"}). All patients provided informed consent, and patient anonymity was preserved. This study was approved by the ethics committee at our institution.

![Flow diagram of patient inclusion in the present study. VO, visceral obesity](AGS3-3-657-g001){#ags312291-fig-0001}

2.2. Definitions {#ags312291-sec-0008}
----------------

Postoperative ileus was defined as a Clavien‐Dindo grade II or higher ileus within 30 days after surgery. Ileus was diagnosed when patients complained of nausea, vomiting, or abdominal distension, and dilatation of the small bowel was radiologically confirmed without obvious small bowel obstruction.[14](#ags312291-bib-0014){ref-type="ref"} All patients underwent computed tomography (CT) prior to surgery, and visceral fat area (VFA) was calculated at the umbilicus level using the SYNAPSE VINCENT (Fuji Medical Systems, Tokyo, Japan) 3‐D image analysis system. Visceral fat, which has a Hounsfield unit threshold of −150 to −30, was coloured red in the images and its area calculated automatically (Figure [2](#ags312291-fig-0002){ref-type="fig"}). VFA ≥100 cm^2^ was considered to indicate VO.[12](#ags312291-bib-0012){ref-type="ref"}, [15](#ags312291-bib-0015){ref-type="ref"}, [16](#ags312291-bib-0016){ref-type="ref"}

![Images from the SYNAPSE VINCENT (Fuji Medical Systems, Tokyo, Japan) 3‐D image‐analysis system. Visceral fat is coloured in red, and its area was automatically calculated. A, Image from a patient with visceral obesity (visceral fat area = 231 cm^2^). B, Image from a patient without visceral obesity (visceral fat area = 23 cm^2^)](AGS3-3-657-g002){#ags312291-fig-0002}

2.3. Data collection {#ags312291-sec-0009}
--------------------

We retrospectively collected demographic and clinicopathological data, including gender, age, BMI, VFA, comorbidities (cardiac comorbidity, neurological comorbidity, hypertension, pulmonary comorbidity, and diabetes mellitus), steroid use, American Society of Anesthesiologists (ASA) physical status classification, neoadjuvant chemotherapy, history of previous abdominal operation, preoperative serum albumin, tumor location, and pathological TNM stage. We also acquired retrospective data regarding the operation, including whether it was laparoscopic or open surgery, level of lymphadenectomy, type of surgical procedure (ie, ileocecal resection, right hemicolectomy, transverse colectomy, left hemicolectomy, sigmoidectomy, anterior resection, low anterior resection, super‐low anterior resection, abdominoperineal resection, intersphincteric resection, Hartmann\'s operation, or total pelvic exenteration), operative time, estimated blood loss, conversion to open surgery, resection of other organs, stoma construction, total intraoperative fluid, amount of intraoperative crystalloid, use of postoperative i.v. fentanyl, length of hospital stay, and postoperative complications (ie, ileus, intra‐abdominal haemorrhage, pelvic and intra‐abdominal abscess, anastomotic leakage, anastomotic hemorrhage, wound complications, urinary infection, and urinary retention).

2.4. Perioperative management {#ags312291-sec-0010}
-----------------------------

For mechanical bowel preparation the day before surgery, patients were given 2000 mL liquid containing polyethylene glycol in the evening, as well as two doses of 12 mg sennoside before bedtime. In the morning on the day of surgery, patients underwent an enema with 60 mL of 50% glycerine. Duration of preoperative fasting was 2 hours for liquids and 18‐24 hours for solids. Prophylaxis with i.v. antibiotics was given 5 minutes before the induction of anesthesia. During prolonged procedures, additional doses of antibiotics were given every 3 hours. To prevent deep vein thrombosis, all patients received mechanical thromboprophylaxis with well‐fitting compression stockings, and intermittent pneumatic compression was carried out during surgery and continued until the patient was fully ambulatory. The nasogastric tube was removed the day after surgery. Postoperative oral liquid intake was usually resumed the day after surgery, and a normal diet was resumed the third day after surgery. Patient mobilization was promoted the day after surgery.

2.5. Propensity score matching {#ags312291-sec-0011}
------------------------------

We used a propensity score‐matching strategy to identify a population from which to estimate the number needed to harm for VO‐related bowel obstruction. To minimize confounding, we used patient demographics and VO risk to calculate propensity scores for VO as derived by a logistic regression model.

Propensity scores were derived using gender, age, comorbidities (ie, cardiac comorbidity, neurological comorbidity, hypertension, pulmonary comorbidity, and diabetes mellitus), steroid use, ASA score, neoadjuvant chemotherapy, history of previous abdominal operation, pathological TNM stage, laparoscopic or open surgery, and surgical procedure.

Propensity matching was carried out according to bowel obstruction risk using nearest‐neighbour matching without replacement, with each VO patient matched to one control patient. A caliper width of 0.2 standard deviation of the logit of the propensity score was used for the developed propensity score, and the same caliper width was used for the expected bowel obstruction and VO probability.

2.6. Statistical analysis {#ags312291-sec-0012}
-------------------------

Demographic data were described across groups as the mean and standard deviation or median and range for continuous variables, and as the absolute count and proportion of patients for categorical variables. Student\'s *t*‐test was used for comparing quantitative variables, and Pearson χ^2^ test or Fisher\'s exact test was used to compare categorical data depending on sample size. Multivariate analysis for risk factors for POI was done using a logistic regression model including the variables with *P* values \<.05 in the univariate analysis. Data were reported as the odds ratio (OR) and 95% confidence interval (CI). Significance was defined as a two‐sided *P* value \<.05. All analyses were carried out using JMP Pro 13.1.0 (SAS Institute).

3. RESULTS {#ags312291-sec-0013}
==========

3.1. Clinicopathological characteristics of patients {#ags312291-sec-0014}
----------------------------------------------------

A total of 417 patients were analyzed in this study. No patient died within 30 days after surgery. Table [1](#ags312291-tbl-0001){ref-type="table"} summarizes the clinicopathological characteristics of all patients. Mean age was 64.9 years (SD 12.9 years), and 259 patients (62.1%) were male. Mean VFA was 88.7 cm^2^ (SD 48.0 cm^2^) and 156 patients (37.4%) met the criteria for VO. Cardiac comorbidities were seen in 64 patients (15.3%), neurological comorbidities in 18 (4.3%), hypertension in 114 (27.3%), pulmonary comorbidities in 19 (4.6%), and diabetes mellitus in 67 (16.1%).

###### 

Clinicopathological characteristics of patients with colorectal cancer in the present study (n = 417)

  Characteristic                
  ---------------------------- ----------------
  Gender                       
  Female                       158 (37.9)
  Male                         259 (62.1)
  Age, years                   64.9 (SD 12.9)
  Body mass index              22.5 (SD 3.4)
  VFA, cm^2^                   88.7 (SD 48.0)
  Comorbidities                
  Cardiac                      64 (15.3)
  Neurological                 18 (4.3)
  Hypertension                 114 (27.3)
  Pulmonary                    19 (4.6)
  Diabetes mellitus            67 (16.1)
  Steroid use                  9 (2.2)
  ASA score                    
  1‐2                          373 (89.4)
  3‐4                          44 (10.6)
  Neoadjuvant chemotherapy     
  Yes                          19 (4.6)
  No                           398 (95.4)
  Previous operation           
  Yes                          93 (22.3)
  No                           324 (77.7)
  Preoperative serum albumin   3.8 (SD 0.5)
  Tumor location               
  Right‐sided colon            116 (27.8)
  Left‐sided colon             129 (30.9)
  Rectum                       172 (41.2)
  pT stage                     
  Tis‐T2                       199 (47.7)
  T3‐T4                        218 (52.3)
  pN stage                     
  N−                           294 (70.5)
  N+                           123 (29.5)
  Synchronous metastasis       
  Yes                          41 (9.8)
  No                           376 (90.2)

Data are presented as n (%) or mean (standard deviation \[SD\]).

Abbreviations: ASA, American Society of Anesthesiologists; VFA, visceral fat area.
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3.2. Surgical and postoperative outcomes {#ags312291-sec-0015}
----------------------------------------

Table [2](#ags312291-tbl-0002){ref-type="table"} presents the surgical and postoperative outcomes of all patients. POI occurred in 18 patients (4.3 per cent), and was treated with fasting and prokinetic agents in six patients, nasogastric tubes in eight patients, and long tube insertion in four patients. Two cases in which adhesiolysis and band dissection were carried out were excluded from the POI group. Median length of hospital stay was significantly longer for patients with POI (median 29 days, range 14‐157 days) than patients without POI (median 15 days, range 7‐223 days; *P *\<* *.001).

###### 

Surgical and postoperative outcomes of patients with colorectal cancer after colorectal resection (n = 417)

  -------------------------------- -------------------
  Laparoscopic surgery             
  Yes                              378 (90.6)
  No                               39 (9.4)
  Lymphadenectomy                  
  D1                               1 (0.2)
  D2                               113 (27.1)
  D3                               303 (72.7)
  Surgical procedure               
  Ileocecal resection              44 (10.6)
  RHC                              63 (15.1)
  Transverse colectomy             9 (2.2)
  LHC                              31 (7.4)
  Sigmoidectomy                    98 (23.5)
  AR                               28 (6.7)
  LAR                              70 (16.8)
  SLAR                             36 (8.6)
  APR                              17 (4.1)
  ISR                              5 (1.2)
  Hartmann\'s operation            6 (1.4)
  Pelvic exenteration              10 (2.4)
  Operative time, min              230 (71‐880)
  Estimated blood loss, mL         50 (5‐11 150)
  Conversion to open surgery       6 (1.4)
  Resection of other organs        37 (8.9)
  Stoma                            52 (12.5)
  Intraoperative crystalloid, mL   1730 (100‐6150)
  Total intraoperative fluid, mL   2070 (300‐13 380)
  Intravenous fentanyl             16 (3.8)
  Complications                    
  POI                              18 (4.3)
  Intra‐abdominal haemorrhage      4 (1.0)
  Pelvic/intra‐abdominal abscess   9 (2.2)
  Anastomotic leakage              16 (3.8)
  Anastomotic haemorrhage          12 (2.9)
  Wound complication               20 (4.8)
  Urinary infection                4 (1.0)
  Urinary retention                4 (1.0)
  Length of stay, days             15 (7‐223)
  -------------------------------- -------------------

Data are presented as n (%) or median (range).

Abbreviations: APR, abdominoperineal resection; AR, anterior resection; ISR, intersphincteric resection; LAR, low anterior resection; LHC, left hemicolectomy; POI, postoperative ileus; RHC, right hemicolectomy; SLAR, super‐low anterior resection.
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3.3. Univariate and multivariate analyses of POI risk factors {#ags312291-sec-0016}
-------------------------------------------------------------

Univariate analysis showed that patients with and without POI differed significantly in eight factors: VO, male gender, neoadjuvant chemotherapy, open surgery, sigmoidectomy, operative time \>230 minutes, estimated blood loss \>50 mL, and pelvic/intra‐abdominal abscess (Table [3](#ags312291-tbl-0003){ref-type="table"}). We carried out a multivariate analysis with seven of these factors, excluding sigmoidectomy due to the complete separation. Three factors remained significant independent risk factors for POI: VO (OR 7.9, 95% CI 1.9‐32.1, *P *=* *.004), open surgery, (OR 6.4, 95% CI 1.6‐26.7, *P *=* *.010) and pelvic/intra‐abdominal abscess (OR 11.0, 95% CI 1.1‐110.2, *P *=* *.041) (Table [3](#ags312291-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analyses for POI risk factors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         POI (n* *=* *18)   No POI (n* *=* *399)   Univariate analysis\                                   Multivariate analysis       
                                                                                   *P* value                                                                          
  -------------------------------------- ------------------ ---------------------- ------------------------------------------------------ --------------------------- ----------
  Male gender                            16 (88.9)          243 (60.9)             **.01** **7**                                          4.1 (0.8‐21.9)              .091

  Age, years                             64.9 (SD 11.4)     65.9 (SD 11.9)         .737                                                                                

  BMI ≥25                                7 (38.9)           74 (18.6)              .060[\*](#ags312291-note-0007){ref-type="fn"}                                       

  VO                                     13 (72.2)          143 (35.8)             **.002**                                               **7.9 (1.9‐32.1)**          **.004**

  Comorbidities                                                                                                                                                       

  Cardiac comorbidity                    1 (5.6)            63 (15.8)              .331[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Neurological comorbidity               0 (0)              18 (4.5)               1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Hypertension                           6 (33.3)           108 (27.1)             .591[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Pulmonary comorbidity                  1 (5.6)            18 (4.5)               .576[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Diabetes mellitus                      4 (22.2)           63 (15.8)              .508[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Steroid use                            0 (0)              9 (2.3)                1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  ASA score 3‐4                          0 (0)              44 (11.0)              .238[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Neoadjuvant chemotherapy               4 (22.2)           15 (3.8)               **.006** [\*](#ags312291-note-0007){ref-type="fn"}     1.5 (0.2‐11.6)              .719

  Previous operation                     2 (11.1)           91 (22.8)              .385[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Preoperative serum albumin             3.9 (SD 0.12)      3.8 (SD 0.03)          .424                                                                                

  Tumor location                                                                                                                                                      

  Right‐sided colon                      4 (22.2)           112 (28.1)             .588                                                                                

  Rectum                                 11 (61.1)          161 (40.4)             .008                                                                                

  pT3‐4 stage                            10 (55.6)          208 (52.1)             .776                                                                                

  pN+ stage                              4 (22.2)           119 (29.8)             .604[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Synchronous metastasis                 4 (22.2)           37 (9.3)               .089[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Open surgery                           7 (38.9)           32 (8.0)               **\<.001** [\*](#ags312291-note-0007){ref-type="fn"}   **6.4 (1.6‐26.7)**          **.010**

  D3 lymphadenectomy                     14 (77.9)          289 (72.4)             .619                                                                                

  Surgical procedure                                                                                                                                                  

  Ileocecal resection                    1 (5.6)            43 (10.8)              .707[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Right hemicolectomy                    3 (16.7)           60 (15.0)              .743[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Transverse colectomy                   0 (0)              9 (2.3)                1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Left hemicolectomy                     3 (16.7)           28 (7.0)               .142[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Sigmoidectomy                          0 (0)              98 (24.6)              **.010** [\*](#ags312291-note-0007){ref-type="fn"}                                 

  Anterior resection                     3 (16.7)           25 (6.3)               .112[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Low anterior resection                 3 (16.7)           67 (16.8)              1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Super‐low anterior resection           2 (11.1)           34 (8.5)               .662[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Abdominoperineal resection             0 (0)              17 (4.3)               1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Intersphincteric resection             0 (0)              3 (0.8)                1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Hartmann\'s operation                  1 (5.6)            2 (0.5)                .124[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Pelvic exenteration                    2 (11.1)           8 (2.0)                .065[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Operative time \>230 min               14 (77.8)          194 (48.6)             **.016**                                               1.7 (0.4‐6.7)               .460

  Estimated blood loss \>50 mL           15 (83.3)          165 (41.4)             **\<.001**                                             2.7 (0.6‐11.7)              .185

  Conversion to open surgery             0 (0)              6 (1.5)                1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Resection of other organs              4 (22.2)           33 (8.3)               .065[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Stoma                                  4 (22.2)           48 (12.0)              .261[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Intraoperative crystalloid \>1730 mL   12 (66.7)          195 (48.9)             .140                                                                                

  Total intraoperative fluid \>2070 mL   13 (72.2)          195 (48.9)             .053                                                                                

  Intravenous fentanyl                   2 (11.1)           14 (3.5)               .148[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Complications                                                                                                                                                       

  Intra‐abdominal hemorrhage             1 (5.6)            3 (0.8)                .162[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Pelvic/intra‐abdominal abscess         3 (16.7)           6 (1.5)                **.005** [\*](#ags312291-note-0007){ref-type="fn"}     **11.0 (1.1‐110.2** **)**   **.041**

  Anastomotic leakage                    1 (5.6)            11 (2.8)               .415[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Anastomotic hemorrhage                 1 (5.9)            8 (2.0)                .424[\*](#ags312291-note-0007){ref-type="fn"}                                       

  Wound complication                     0 (0)              20 (5.0)               1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Urinary infection                      0 (0)              4 (1.0)                1.000[\*](#ags312291-note-0007){ref-type="fn"}                                      

  Urinary retention                      1 (5.6)            3 (0.8)                .162[\*](#ags312291-note-0007){ref-type="fn"}                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as n (%) or mean (standard deviation \[SD\]) unless otherwise noted.

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; POI, postoperative ileus; VO, visceral obesity.

\*Fisher\'s exact test. Bold text indicates a statistically significant difference with a *P*‐value less than 0.05.

John Wiley & Sons, Ltd

3.4. Propensity score matching {#ags312291-sec-0017}
------------------------------

To reduce the possibility of selection bias, we conducted propensity score matching. A total of 256 cases were matched (128 cases each). Table [4](#ags312291-tbl-0004){ref-type="table"} presents their clinicopathological characteristics and preoperative features. Among all 417 patients, patients with and without VO had significant differences in gender, hypertension, diabetes mellitus, neoadjuvant chemotherapy, preoperative serum albumin, and synchronous metastasis. After matching, the two groups did not show any significant differences in clinicopathological characteristics and preoperative features (Table [4](#ags312291-tbl-0004){ref-type="table"}).

###### 

Clinicopathological characteristics and preoperative features of patients

                                 All patients    Matched patients                                                                                    
  ------------------------------ --------------- ------------------ ----------------------------------------------- ---------------- --------------- ------------------------------------------------
  Gender, male                   119 (76.3)      140 (53.6)         **\<.001**                                      92 (71.9)        93 (72.7)       .889
  Age, years                     65.4 (SD 1.0)   64.6 (SD 0.8)      .510                                            65.3 (SD 1.1)    65.5 (SD 1.1)   .881
  Comorbidities                                                                                                                                      
  Cardiac comorbidity            25 (16.0)       39 (14.9)          .767                                            18 (14.1)        21 (16.4)       .602
  Neurological comorbidity       8 (5.1)         10 (3.8)           .528                                            7 (5.5)          7 (5.5)         1.000
  Hypertension                   57 (36.5)       57 (21.8)          **.001**                                        41 (32.0)        39 (30.5)       .787
  Pulmonary comorbidity          6 (3.9)         13 (5.0)           .591                                            5 (3.9)          5 (3.9)         1.000
  Diabetes mellitus              34 (21.8)       33 (12.6)          **.014**                                        25 (19.5)        22 (17.2)       .628
  Steroid use                    5 (3.2)         4 (1.5)            .304[\*](#ags312291-note-0010){ref-type="fn"}   4 (3.1)          4 (3.1)         1.000[\*](#ags312291-note-0010){ref-type="fn"}
  ASA score (3‐4)                15 (9.6)        29 (11.1)          .631                                            11 (8.6)         10 (7.8)        .820
  Neoadjuvant chemotherapy       3 (1.9)         16 (6.1)           **.046**                                        3 (2.3)          1 (0.8)         .622[\*](#ags312291-note-0010){ref-type="fn"}
  Previous operation             39 (25.0)       54 (20.7)          .306                                            30 (23.4)        25 (19.5)       .447
  Preoperative serum albumin     3.9 (SD 0.04)   3.7 (SD 0.03)      **.013**                                        33.9 (SD 0.05)   3.8 (SD 0.05)   .165
  Laparoscopic surgery           146 (93.6)      232 (88.9)         .111                                            117 (91.4)       118 (92.2)      .820
  D3 lymphadenectomy             107 (68.6)      196 (75.1)         .149                                            87 (68.0)        85 (66.4)       .790
  Surgical procedure                                                                                                                                 
  Ileocecal resection            13 (8.3)        31 (11.9)          .254                                            11 (8.6)         13 (10.2)       .668
  Right hemicolectomy            29 (18.6)       34 (13.0)          .125                                            25 (19.5)        21 (16.4)       .515
  Transverse colectomy           5 (3.2)         4 (1.5)            .304[\*](#ags312291-note-0010){ref-type="fn"}   3 (2.3)          2 (1.6)         1.000[\*](#ags312291-note-0010){ref-type="fn"}
  Left hemicolectomy             15 (9.6)        16 (6.1)           .189                                            11 (8.6)         13 (10.2)       .668
  Sigmoidectomy                  31 (19.9)       67 (25.7)          .177                                            28 (21.9)        29 (22.7)       .881
  Anterior resection             10 (6.4)        18 (6.9)           .849                                            10 (7.8)         10 (7.8)        1.000
  Low anterior resection         30 (19.2)       40 (15.3)          .302                                            23 (18.0)        22 (17.2)       .870
  Super‐low anterior resection   15 (9.6)        21 (8.0)           .581                                            13 (10.2)        13 (10.2)       1.000
  Abdominoperineal resection     4 (2.6)         13 (5.0)           .227                                            3 (2.3)          3 (2.3)         1.000[\*](#ags312291-note-0010){ref-type="fn"}
  Intersphincteric resection     0 (0)           3 (1.1)            .296[\*](#ags312291-note-0010){ref-type="fn"}   0 (0)            0 (0)           
  Hartmann\'s operation          0 (0)           3 (1.1)            .296[\*](#ags312291-note-0010){ref-type="fn"}   0 (0)            0 (0)           
  Pelvic exenteration            1 (0.6)         9 (3.4)            .098[\*](#ags312291-note-0010){ref-type="fn"}   1 (0.8)          0 (0)           1.000[\*](#ags312291-note-0010){ref-type="fn"}
  pT (3‐4)                       85 (54.5)       133 (51.0)         .485                                            65 (50.8)        66 (51.6)       .901
  pN (+)                         45 (28.8)       78 (29.9)          .822                                            37 (28.9)        37 (28.9)       1.000
  Synchronous metastasis         22 (14.1)       19 (7.3)           **.024**                                        11 (8.6)         12 (9.4)        .827

Data are presented as n (%) or mean (standard deviation \[SD\]).

Abbreviations: ASA, American Society of Anesthesiologists; VO, visceral obesity.

\*Fisher\'s exact test. Bold text indicates a statistically significant difference with a *P*‐value less than 0.05.
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3.5. Surgical and postoperative outcomes in matched patients {#ags312291-sec-0018}
------------------------------------------------------------

Table [5](#ags312291-tbl-0005){ref-type="table"} shows the surgical and postoperative outcomes of the 256 matched patients. POI occurred in 14 (5.5 per cent) of the 256 matched patients and was treated with fasting and prokinetic agents in six patients, nasogastric tubes in seven patients, and long tube insertion in one patient. Median length of hospital stay was significantly longer among patients with POI (median 26 days, range 14‐50 days) than among patients without POI (median 15 days, range 8‐90 days; *P *=* *.012).

###### 

Surgical and postoperative outcomes for matched patients (n = 256)

  -------------------------------- -------------------
  Laparoscopic surgery             
  Yes                              235 (91.8)
  No                               21 (8.2)
  Lymphadenectomy                  
  D1                               1 (0.4)
  D2                               83 (32.4)
  D3                               172 (67.2)
  Operative time, min              228.5 (113‐729)
  Estimated blood loss, mL         45 (5‐5660)
  Conversion to open surgery       5 (2.0)
  Resection of other organs        17 (6.6)
  Stoma                            24 (9.4)
  Intraoperative crystalloid, mL   1750 (300‐6150)
  Total intraoperative fluid, mL   2100 (300‐10 250)
  Intravenous fentanyl             7 (2.7)
  Complications                    
  POI                              14 (5.5)
  Intra‐abdominal hemorrhage       1 (0.4)
  Pelvic/intra‐abdominal abscess   4 (1.6)
  Anastomotic leakage              12 (4.7)
  Anastomotic hemorrhage           8 (3.1)
  Wound complication               13 (5.1)
  Urinary infection                1 (0.4)
  Urinary retention                2 (0.8)
  Length of stay, days             15 (8‐90)
  -------------------------------- -------------------

Data are presented as median (range) or n (%).

Abbreviation: POI, postoperative ileus.

John Wiley & Sons, Ltd

3.6. Univariate and multivariate analyses of POI risk factors in matched patients {#ags312291-sec-0019}
---------------------------------------------------------------------------------

Univariate analysis showed that patients with and without POI had significantly different rates of VO, open surgery, operation time \>228.5 minutes, and estimated blood loss \>50 mL (Table [6](#ags312291-tbl-0006){ref-type="table"}). Two of these factors, VO and open surgery, were also independent risk factors in the multivariate analysis: VO (OR 6.2, 95% CI 1.3‐30.4, *P *=* *.025), and open surgery (OR 9.1, 95% CI 2.0‐40.5, *P *=* *.004).

###### 

Univariate and multivariate analyses of POI risk factors using matched patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         Ileus (n* *=* *14)   No ileus (n* *=* *242)   Univariate analysis\                                 Multivariate analysis     
                                                                                       *P* value                                                                      
  -------------------------------------- -------------------- ------------------------ ---------------------------------------------------- ------------------------- ----------
  BMI ≥25                                5 (35.7)             56 (23.1)                .332[\*](#ags312291-note-0015){ref-type="fn"}                                   

  Open surgery                           5 (35.7)             16 (6.6)                 **.003** [\*](#ags312291-note-0015){ref-type="fn"}   **9.1 (2.0‐40.** **5)**   **.004**

  D3 lymphadenectomy                     10 (71.4)            162 (66.9)               1.000[\*](#ags312291-note-0015){ref-type="fn"}                                  

  Intra‐abdominal hemorrhage             0 (0)                1 (0.4)                  1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Pelvic/intra‐abdominal abscess         1 (7.1)              3 (1.2)                  .203[\*](#ags312291-note-0015){ref-type="fn"}                                  

  Anastomotic leakage                    0 (0)                12 (5.0)                 1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Anastomotic hemorrhage                 0 (0)                8 (3.3)                  1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Wound complication                     0 (0)                13 (5.4)                 1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Urinary infection                      0 (0)                1 (0.4)                  1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Urinary retention                      0 (0)                2 (0.8)                  1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Stoma                                  3 (21.4)             21 (8.7)                 .132[\*](#ags312291-note-0015){ref-type="fn"}                                  

  Operation time \>228.5 min             11 (78.6)            117 (48.3)               **.028**                                             3.5 (0.788‐16.0)          .099‐

  Estimated blood loss \>45 mL           12 (85.7)            116 (47.9)               **.006**                                             2.4 (0.460‐12.8)          .296

  Conversion to open surgery             0 (0)                5 (2.1)                  1.000[\*](#ags312291-note-0015){ref-type="fn"}                                 

  Resection of other organs              3 (21.4)             14 (5.8)                 .056[\*](#ags312291-note-0015){ref-type="fn"}                                  

  Intraoperative crystalloid \>1750 mL   9 (64.3)             114 (47.1)               .211                                                                            

  Total intraoperative fluid \>2100 mL   8 (57.1)             114 (47.1)               .465                                                                            

  Intravenous fentanyl                   1 (7.1)              6 (2.5)                  .329[\*](#ags312291-note-0015){ref-type="fn"}                                   

  Visceral obesity                       12 (85.7)            116 (47.9)               **.006**                                             **6.2 (1.3‐30.4** **)**   **.025**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as n (%) unless otherwise noted.

Abbreviations: BMI, body mass index; POI, postoperative ileus.

\*Fisher\'s exact test. Bold text indicates a statistically significant difference with a p‐value less than 0.05.
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4. DISCUSSION {#ags312291-sec-0020}
=============

Postoperative ileus is a frequent postoperative complication after colorectal surgery at our institution. POI is reported to result in more extended hospital stays and higher costs, as mentioned earlier. Therefore, we assessed the risk factors for POI in this setting. To effectively prevent POI, we must identify risk factors that can be assessed prior to surgery. In multivariate analysis including all 417 patients in our study cohort, we found that VO, open surgery, and pelvic/intra‐abdominal abscess are independent risk factors for POI. Of these, VO is a predictive factor that can be preoperatively assessed. Thus, we focused on analyzing VO as a risk factor for POI. As obesity is associated with both tumour initiation and progression in colorectal cancer,[17](#ags312291-bib-0017){ref-type="ref"}, [18](#ags312291-bib-0018){ref-type="ref"} it is commonly encountered among patients requiring colorectal surgery for colorectal cancer.

Previous reports have shown that, compared to BMI, VO is more strongly associated with complications after colorectal surgery.[12](#ags312291-bib-0012){ref-type="ref"}, [13](#ags312291-bib-0013){ref-type="ref"} Among 338 patients who underwent colorectal resection for colorectal cancer, and 75 patients who underwent total gastrectomy for gastric cancer, VO was more strongly related to incidences of anastomotic leakage and surgical site infection than high BMI.[13](#ags312291-bib-0013){ref-type="ref"}, [19](#ags312291-bib-0019){ref-type="ref"} However, to the best of our knowledge, no previous study has included multivariable analysis to assess VO as a risk factor for POI, and the present study is the first to show that VO may be a risk factor for POI after surgery for colorectal cancer.

Some studies have reported that BMI, which is widely used for the assessment of general obesity, is a risk factor for POI.[6](#ags312291-bib-0006){ref-type="ref"}, [11](#ags312291-bib-0011){ref-type="ref"} He et al. carried out a meta‐analysis, showing that BMI \>30 is a risk factor for POI after laparoscopic colorectal surgery (OR 1.73, *P *=* *.02); however, they did not assess VO as a potential risk factor.[11](#ags312291-bib-0011){ref-type="ref"} In contrast, our present findings did not indicate that higher BMI is a risk factor for POI, although we used a cut‐off of 25 for higher BMI because only eight of our 417 patients had a BMI \>30. This is compatible with other reports indicating that BMI is not a risk factor for POI after colorectal surgery.[3](#ags312291-bib-0003){ref-type="ref"}, [20](#ags312291-bib-0020){ref-type="ref"} In the present study, VO was an independent risk factor for POI, suggesting that VO is a more accurate predictor of POI after colorectal surgery than BMI. OR for VO and POI was 7.9 in the multivariate analysis, and 6.2 after propensity score matching, indicating that VO may have an impact on postoperative outcome as well as on POI.

Preoperative assessment of VO as a predictor of POI may enable action to be taken before surgery to prevent or reduce POI. Numerous strategies for reducing POI have been explored. In a systematic review, Chapman et al showed that minimally invasive surgery, protocol‐driven recovery (eg, early feeding and opioid‐avoidance strategies), and measures to avoid major inflammatory events (eg, anastomotic leakage) offer the best chances of reducing POI.[21](#ags312291-bib-0021){ref-type="ref"}

Most reports on VO as a risk factor for postoperative complications do not discuss the mechanisms by which adipose tissue causes inflammation. Stoffels et al showed that interleukin‐1 (IL‐1) signaling by IL‐1 receptor 1 and myeloid differentiation primary response 88 (MyD88) is required for POI development after intestinal manipulation in mice.[22](#ags312291-bib-0022){ref-type="ref"} Studies of adipose tissue have shown that human visceral adipose tissue, which is considered a major contributor to increased levels of circulating inflammatory cytokines, contains higher levels of IL‐1α, IL‐1β, and IL‐1R antagonist compared to subcutaneous adipose tissue.[23](#ags312291-bib-0023){ref-type="ref"}, [24](#ags312291-bib-0024){ref-type="ref"}, [25](#ags312291-bib-0025){ref-type="ref"} Reasonably, IL‐1α and IL‐1β, which are both major components of the IL‐1 family, may be released from adipose tissue as a result of intraoperative manipulation of the intestines and mesentery, leading to the development of POI.

Median hospital stay in the present study was 14 days, even among patients without POI, although the length of hospital stay after surgery for elective colorectal cancer has been reported to be 4‐12 days.[21](#ags312291-bib-0021){ref-type="ref"}, [26](#ags312291-bib-0026){ref-type="ref"} Reason for the longer stay at our institution compared to current standards in most Western countries may be that we decide the date of discharge in part on the bed occupancy rate, as it is important for hospital management.[27](#ags312291-bib-0027){ref-type="ref"}

Use of i.v. fentanyl after surgery was not a risk factor for POI in the present study, possibly because few patients were given i.v. fentanyl. We do not use epidural anesthesia or i.v. fentanyl after laparoscopic surgery for colorectal cancer unless we cannot control postoperative pain without opioids. Most of the patients (90.6%) underwent laparoscopic surgery, and i.v. fentanyl was given only to 16 (3.8%) of the 417 patients.

The present study has several limitations. First, the retrospective design of this study has several intrinsic limitations. To reduce the risk of selection bias, we carried out propensity score matching. Second, by the definition used for POI, there was a possibility of including patients with small bowel obstruction into the POI group although we excluded two cases with blatant small bowel obstruction. However, some perioperative interventions for patients with VO will be effective prevention for both POI and small bowel obstruction. Third, this study was carried out at a single institution with a moderate number of patients. Further studies should be conducted in larger populations from multiple institutions. Fourth, we did not assess postoperative levels of IL‐1 family members in the patients, but VO can be used as a surrogate marker of these levels. Fifth, the enhanced recovery after surgery (ERAS) protocol was not introduced at our institution. POI prevention is one of the aims of the ERAS protocol,[28](#ags312291-bib-0028){ref-type="ref"}, [29](#ags312291-bib-0029){ref-type="ref"} and Ni et al reported that ERAS resulted in shorter average length of postoperative hospital stay, time to first flatus, and time to first defecation than traditional perioperative care after colorectal surgery in 1298 patients in a meta‐analysis of randomized controlled trials.[29](#ags312291-bib-0029){ref-type="ref"} They also reported that the overall complication rates were significantly lower with ERAS than with traditional perioperative care. Although, currently, the ERAS protocol is not common in Japan, it may be effective, especially for patients with VO. Despite these limitations, we think that the present study is of great importance because it is the first report of VO as a risk factor for POI after surgery among patients with colorectal cancer.

In conclusion, the present study showed that VO is an independent risk factor for POI after colorectal resection among an entire cohort of 417 patients and among 256 matched patients. This finding enables the assessment of POI risk before surgery by checking VFA, as VFA \>100 cm^2^ may indicate a need for perioperative interventions, such as opioid‐avoidance strategies and giving prokinetic agents before and after surgery. Furthermore, selectively introducing the ERAS protocol in Japan for patients with VO may be acceptable and effective. The present findings should be verified in a prospective multicenter study with a greater number of patients.
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